Trial Profile
A Single-arm, Multi-center Exploratory Clinical Study of Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 24 Oct 2023 Updated Results investigating the efficacy and safety of anlotinib plus TQB2450 as first-line therapy for patients with advanced ESCC, presented at the 48th European Society for Medical Oncology Congress
- 06 Jun 2023 Preliminary results (At the data cut-off date , Dec, 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 16 May 2023 Planned End Date changed from 1 May 2024 to 1 Sep 2024.